Introduction {#s1}
============

Cerebral small vessel disease (SVD) is prevalent in older people and generally considered as a common cause of stroke, gait disturbances, and vascular cognitive impairment ([@B1], [@B2]). Brain magnetic resonance imaging (MRI) is most commonly used in clinical practice for detection of SVD and also the gold standard imaging for visualization of SVD *in vivo* ([@B3]). Imaging features of SVD on MRI encompass lacunes, white matter hyperintensities (WMH), cerebral microbleeds (CMB), and enlarged perivascular spaces (EPVS) ([@B4]). Lacunes, WMH and EPVS were associated with increased risk of stroke recurrence, mortality, disability, and worse clinical outcomes ([@B5]--[@B9]). SVD is thought to be a poor prognostic marker of stroke ([@B10]).

Previous studies mainly focused on the effect of individual SVD feature on prognosis of acute ischemic stroke. Whereas, the features of SVD may occur simultaneously in a patient at clinical practice, it seems rather artificial to investigate the presence of only one feature while disregarding the others. Recently, a total SVD score has been proposed and validated ([@B8], [@B11], [@B12]), assessing the cumulative effect of different SVD features on the whole brain rather than considering individual features separately. Several recent studies have suggested a role for the total SVD score in predicting poor life quality ([@B13]), recurrent stroke ([@B8]), and mortality ([@B14]) after stroke.

However, the information about prognostic implications of the total SVD burden for 90 days functional outcome is scarce. Only two studies had reported the relationship of total SVD burden and 90 days functional outcome among patients with acute ischemic stroke ([@B3], [@B7]), but they just evaluated the combination effect of lacunes and WMH. Whether the total SVD burden is superior to individual SVD feature in prediction of functional outcome after stroke still needs further investigation. Understanding the factors influencing functional outcome is highly valuable in clinical management of stroke victims, and may help to guide rehabilitation strategies to improve outcomes.

Thus, the purpose of our study was to investigate the predictive efficacy of total SVD burden for functional outcome at 90 days after acute ischemic stroke. Since the evaluation of CMB is limited as susceptibility weighted imaging (SWI) and gradient recalled echo (GRE) sequence were not routine sequences of MRI for patients with acute ischemic stroke in most hospitals of China, the use of the total SVD score ([@B11]) in clinical practice is limited in China. Therefore, we only chose features of SVD (lacunes, WMH, and EPVS) that were available with routine sequence of MRI, to ensure feasibility of use and transferability of results on clinical practice.

Materials and Methods {#s2}
=====================

Study Population
----------------

For this retrospective analysis, we used prospectively collected data from a database involving consecutive patients with acute ischemic stroke admitted between April 2017 and January 2018 at the Department of Neurology of First Affiliated Hospital of Chongqing Medical University, a large tertiary medical center in Chongqing. Chongqing is the largest municipality in Southwest China, with a population of 35 million ([@B15]). Acute ischemic stroke was diagnosed if there were new focal neurological deficits explained by relevant lesions detected on diffusion-weighted imaging (DWI) or computed tomography (CT). Patients were eligible for the study if they had cerebral MRI on admission. The exclusion criteria are as follows: 1) patients with contraindication to MRI or with poor quality of MRI; and 2) patients lack of 90-day modified Rankin Scale (mRS) score. All patients underwent standard evaluation, treatment, and rehabilitation that adhered to guidelines for ischemic stroke. The study was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University, and all participants gave written, informed consent. The study protocol was performed in accordance with the Declaration of Helsinki.

Collection of Demographic and Clinical Data
-------------------------------------------

Clinical data were collected on admission through a specified questionnaire that included demographic data and the presence of vascular risk factors.

Body mass index (BMI) was calculated as weight divided by the square of height. Hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg, or used antihypertensive drug ([@B16]). Diabetes mellitus was defined as fasting plasma glucose level ≥7.0 mmol/L, or used hypoglycemic drug/insulin injection ([@B17]). Hypercholesterolemia was defined as a low-density lipoprotein cholesterol concentration ≥3.4 mmol/L or a total cholesterol concentration ≥5.2 mmol/L, or previous diagnosis of hypercholesterolemia with current use of cholesterol-lowering medications ([@B18]). Current smoking was defined as consuming ≥1 cigarette each day or quit smoking ≤ 1 year; alcohol consumption was defined as alcohol consumption ≥8 g every week ([@B19]). The definition of coronary heart disease and previous stroke was according to the International Classification of Diseases, 9th version ([@B20]).

National Institutes of Health Stroke Scale (NIHSS) score, mRS score, and time from onset to admission were assessed at the time of initial presentation as part of the admission workup. Hospital stay was recorded at discharge. Stroke subtypes were determined based on the modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria: large artery atherosclerosis, cardioembolism, small vessel occlusion, other determined, or undetermined stroke ([@B21]).

Outcome Measures
----------------

The functional outcome was measured with the mRS at 90 days and defined as i) excellent outcome (mRS ≤ 1) and ii) good outcome (mRS ≤ 2) ([@B7], [@B22]). We considered the mRS score as dichotomous outcome (0--1: excellent outcome vs. 2--6: disability/death; 0--2: good outcome vs. 3--6: functional dependence/death) and ordinal scale (0--6) ([@B3], [@B7]).

Imaging
-------

Brain MRI was performed on a 3.0-Tesla MRI system scanner (GE Medical Systems, Waukesha, WI, USA), and the images contained T1-weighted, T2-weighted, fluid attenuated inversion recovery (FLAIR), and DWI sequences. A stroke neurologist (Huo, YC), trained in MRI assessment and blinded to clinical data, rated all the available scans.

Lacunes were defined as rounded or ovoid lesions, \>3 and \<20 mm diameter, in the basal ganglia, internal capsule, centrum semiovale, or brainstem, of CSF signal intensity on T2 and FLAIR, generally with a hyperintense rim on FLAIR and no increased signal on DWI ([@B4]). WMH were diagnosed and scored by the revised version of the visual scale of Fazekas et al. ([@B23]). In the Fazekas rating scale, WMH are divided into periventricular white matter hyperintensities (PVWMH) and deep white matter hyperintensities (DWMH) according to anatomic location. PVWMH are scored as follows: none (0, no lesion), mild (1, caps or a pencil-thin lining), moderate (2, smooth halo), and severe (3, irregular lesions extending into the deep white matter). DWMH are scored as follows: none (0, no lesion), mild (1, punctuate foci), moderate (2, beginning confluent foci), and severe (3, large confluent lesions). EPVS were defined as small (\<3 mm) punctate (if perpendicular to the plane of scan) or linear (if longitudinal to the plane of scan) lesions with signal intensity similar to that of cerebrospinal fluid on all sequence spaces and without a T2-hyperintense rim on FLAIR imaging ([@B4]). EPVS were counted at the level of centrum semiovale (CS) and basal ganglia (BG), respectively, with a validated four-point visual rating scale (0 = none; 1 = 1--10; 2 = 11--20; 3 = 21--40; and 4 = \>40) ([@B24]). At both levels, we identified the slide in the most affected hemisphere only. Limited intrarater reliability testing (50 scans) showed a good reliability with kappa values of 0.81 for the presence of lacunes, 0.89 for PVWMH, 0.85 for DWMH, and 0.76 for EPVS.

To calculate the total SVD burden, we evaluated lacunes, WMH, and EPVS based on the ordinal scale developed by Klarenbeek et al. ([@B11]), which had been validated in several large studies ([@B8], [@B12]--[@B14]). A point was awarded if one or more lacunes were present, or WMH were extensive (DWMH Fazekas score 2 or 3, or PVWMH Fazekas score 3), or EPVS in BG were moderate to severe (scored 2--4), respectively. The three sub-scores were then summed up to generate a total SVD burden that ranged from 0 to 3.

Statistical Analysis
--------------------

Statistical analyses were performed by SPSS 19.0 software (IBM Corp., Armonk, NY, USA) and STATA 12.0 software (STATA Corp., College Station, Texas, USA). The total SVD burden was considered as ordinal scale (0--3), reflecting no features to all three features of SVD. Continuous variables were presented as mean ± standard deviations (SD) or as median and interquartile range (IQR) as appropriate. In univariate analyses, normally distributed continuous variables were compared with one-way analysis of variance or Student\'s *t*-test, and the variables not normally distributed were compared with Kruskal--Wallis *H* test or Mann--Whitney *U* test. Categorical variables were presented as percentages and were compared with Pearson\'s chi square test or Fisher\'s exact test.

Binary logistic regression was used to analyze the associations between SVD and functional outcomes (excellent outcome and good outcome). Firstly, unadjusted associations of individual SVD feature and total SVD burden with functional outcomes were analyzed. Secondly, adjusted associations between total burden of SVD and functional outcomes were analyzed. All multivariable analyses were first adjusted for age and sex (Model 1) and additionally adjusted for potential confounders (including age, sex, hypertension, diabetes mellitus, hypercholesterolemia, coronary heart disease, previous stroke, current smoking, alcohol consumption, proximal vessel occlusion, stroke subtype, baseline NIHSS, baseline mRS and hospital stay; Model 2). The results are shown as odds ratio (OR) and 95% confidence intervals (CI). A two-tailed *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the Study Population
---------------------------------------

A total of 557 patients with acute ischemic stroke were screened at baseline, among which 132 patients with contraindication to MRI or with poor quality of MRI and 9 patients lacking 90-day mRS scores were excluded. Finally, 416 patients with acute ischemic stroke were included in the final analysis. There were 278 males (66.8%) and 138 females (33.2%). The average age of the patients was 67 years (age range 19--94). Baseline characteristics of the study population stratified by burden of SVD are presented in [Table 1](#T1){ref-type="table"}. For SVD burden, 183 patients (44.0%) had an SVD burden of 0, showing no signs of lacunes, WMH, and EPVS; 139 patients (33.4%) had 1 feature of SVD; 80 patients (19.2%) presented with 2 features; and 14 patients (3.4%) presented with all 3 features.

###### 

Baseline characteristics of study population stratified by burden of small vessel disease.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
                                       **SVD = 0**\             **SVD = 1**\             **SVD = 2**\             **SVD = 3**\             ***P-*value**
                                       **(*n* = 183)**          **(*n* = 139)**          **(*n* = 80)**           **(*n* = 14)**           
  ------------------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ---------------
  **Demographics**                                                                                                                         

  Age, years, median (IQR)             63 (54 -- 69)            69 (60 -- 77)            72 (64 -- 80)            81 (68 -- 83)            0.000

  Sex, male, *n* (%)                   114 (62.3)               96 (69.1)                57 (71.3)                11 (78.6)                0.334

  BMI, median (IQR)                    24.22 (21.94 -- 25.84)   23.47 (20.96 -- 25.54)   24.10 (21.26 -- 25.95)   23.70 (21.61 -- 25.05)   0.541

  **Clinical history**                                                                                                                     

  Hypertension, *n* (%)                104 (56.8)               107 (77.0)               66 (82.5)                11 (78.6)                0.000

  Diabetes mellitus, *n* (%)           63 (34.4)                73 (52.5)                41 (51.3)                6 (42.9)                 0.006

  Hypercholesterolemia, *n* (%)        68 (37.2)                54 (38.8)                37 (46.3)                7 (50.0)                 0.461

  Previous stroke, *n* (%)             24 (13.1)                38 (27.3)                22 (27.5)                3 (21.4)                 0.004

  Proximal vessel occlusion, *n* (%)   19 (10.4)                18 (12.9)                9 (11.3)                 0 (0)                    0.506

  Thrombolysis, *n* (%)                14 (7.7)                 13 (9.4)                 5 (6.3)                  1 (7.1)                  0.867

  Stroke subtype, *n* (%)                                                                                                                  0.052

  Large artery atherosclerosis         48 (26.2)                49 (35.3)                33 (41.3)                6 (42.9)                 

  Cardioembolism                       38 (20.8)                27 (19.4)                8 (10.0)                 3 (21.4)                 

  Small vessel occlusion               75 (41.0)                45 (32.4)                25 (31.3)                2 (14.3)                 

  Undetermined                         8 (4.4)                  3 (2.2)                  1 (1.3)                  0 (0.0)                  

  Other determined                     14 (7.7)                 15 (10.8)                13 (16.3)                3 (21.4)                 

  **Clinical variables**                                                                                                                   

  Baseline NIHSS, median (IQR)         3 (1 -- 7)               4 (2 -- 7)               4 (2 -- 8)               5 (3 -- 8)               0.093

  Baseline mRS score, median (IQR)     0 (0 -- 0)               0 (0 -- 0)               0 (0 -- 1)               0 (0 -- 2)               0.000

  90-day mRS score, median (IQR)       1 (0 -- 2)               1 (1 -- 2)               2 (1 -- 3)               3 (2 -- 4)               0.000
  --------------------------------------------------------------------------------------------------------------------------------------------------------

*SVD, small vessel disease; IQR, interquartile range; BMI, body mass index; NIHSS, National Institute of Health Stroke Scale; mRS, modified Ranking scale*.

Age, the proportion of hypertension, diabetes mellitus, and previous stroke differed significantly with increasing burden (0--3) of SVD (*p* \< 0.05, [Table 1](#T1){ref-type="table"}). Sex, BMI, stroke subtype, and the presence of other vascular risk factors showed no differences among groups (*p* \> 0.05).

Functional Outcome
------------------

A total of 251 (60.3%) patients had excellent outcome (mRS ≤ 1) and 315 (75.7%) patients had good outcome (mRS ≤ 2) at 3 months. The incidence of excellent outcome (67.8, 61.2, 48.8, 21.4%, *p*~trend~ = 0.001) and good outcome (80.9, 77.0, 67.5, 42.9%, *p*~trend~ = 0.004) decreased significantly with increasing burden (0--3) of SVD. However, the 90-day mRS score and the proportion of 90-day mortality in patients with increasing SVD burden increased significantly (*p* \< 0.001, [Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}).

![Distribution of mRS score at 90 days in all patients according to burden of small vessel disease. The percentage of participants with the mRS obtained at 90 days is shown in each cell. mRS, modified Rankin Scale; SVD, small vessel disease.](fneur-10-00808-g0001){#F1}

Clinical and imaging characteristics of functional outcomes are presented in [Table 2](#T2){ref-type="table"}. Patients with excellent outcome or good outcome were younger and had a lower proportion of diabetes mellitus, coronary heart disease, previous stroke, and proximal vessel occlusion; a lower score of baseline NIHSS; and a shorter time of hospital stay as compared to the patients with disability/death or functional dependence/death (*p* \< 0.05). In regard to stroke subtypes, 136 (32.7%) had large artery atherosclerosis, 76 (18.3%) had cardioembolism, and 147 (35.3%) had small vessel occlusion. The distribution of stroke subtypes differed significantly among all groups (*p* \< 0.001, [Table 2](#T2){ref-type="table"}).

###### 

Clinical and imaging characteristics of the study population based on functional outcomes.

                                                **Functional Outcomes**                                                                                      
  --------------------------------------------- ------------------------- ------------------------ ------- ------------------------ ------------------------ -------
  **Demographics**                                                                                                                                           
  Age, years, median (IQR)                      65 (57 -- 74)             68 (60 -- 77)            0.043   66 (57 -- 74)            71 (60 -- 80)            0.006
  Sex, male, *n* (%)                            173 (68.9)                105 (63.6)               0.262   212 (67.3)               66 (65.3)                0.717
  BMI, median (IQR)                             23.88 (21.64 -- 25.95)    24.01 (21.25 -- 25.71)   0.523   24.06 (21.74 -- 25.92)   23.44 (21.22 -- 25.46)   0.107
  **Clinical history**                                                                                                                                       
  Hypertension, *n* (%)                         171 (68.1)                117 (70.9)               0.548   220 (69.8)               68 (67.3)                0.634
  Diabetes mellitus, *n* (%)                    94 (37.5)                 89 (53.9)                0.001   129 (41.0)               54 (53.5)                0.027
  Hypercholesterolemia, *n* (%)                 108 (43.0)                58 (35.2)                0.109   129 (41.0)               37 (36.6)                0.441
  Coronary heart disease, *n* (%)               34 (13.5)                 37 (22.4)                0.019   45 (14.3)                26 (25.7)                0.008
  Previous stroke, *n* (%)                      42 (16.7)                 45 (27.3)                0.01    52 (16.5)                35 (34.7)                0.000
  Current smoking, *n* (%)                      106 (42.2)                67 (40.6)                0.742   135 (42.9)               38 (37.6)                0.353
  Alcohol consumption, *n* (%)                  68 (27.1)                 32 (19.4)                0.072   81 (25.7)                19 (18.8)                0.158
  Proximal vessel occlusion, *n* (%)            13 (5.2)                  33 (20.0)                0.000   27 (8.6)                 19 (18.8)                0.006
  Thrombolysis, *n* (%)                         18 (7.2)                  15 (9.1)                 0.478   24 (7.6)                 9 (8.9)                  0.676
  Stroke subtype, *n* (%)                                                                          0.000                                                     0.000
  Large artery atherosclerosis                  66 (26.3)                 70 (42.4)                        90 (28.6)                46 (45.5)                
  Cardioembolism                                41 (16.3)                 35 (21.2)                        54 (17.1)                22 (21.8)                
  Small vessel occlusion                        115 (45.8)                32 (19.4)                        133 (42.2)               14 (13.9)                
  Undetermined                                  6 (2.4)                   6 (3.6)                          8 (2.5)                  4 (4.0)                  
  Other determined                              23 (9.2)                  22 (13.3)                        30 (9.5)                 15 (14.9)                
  **Clinical variables**                                                                                                                                     
  Baseline NIHSS, median (IQR)                  3 (1 -- 5)                7 (4 -- 11)              0.000   3 (1 -- 5)               8 (5 -- 14)              0.000
  Hospital stay, day, median (IQR)              12 (9 -- 14)              15 (11 -- 21)            0.000   12 (10 -- 15)            15 (10 -- 23)            0.000
  Onset to admission time, hour, median (IQR)   17.5 (5.0 -- 38.5)        15.3 (5.0 -- 40.8)       0.968   17.5 (5.5 -- 42.0)       11.8 (4.0 -- 36.3)       0.204
  **SVD**                                                                                                                                                    
  Lacunes, median (IQR)                         0 (0 -- 1)                1 (0 -- 2)               0.000   0 (0 -- 1)               1 (0 -- 2)               0.001
  WMH, median (IQR)                             0 (0 -- 0)                0 (0 -- 1)               0.004   0 (0 -- 0)               0 (0 -- 1)               0.008
  EPVS, median (IQR)                            0 (0 -- 0)                0 (0 -- 0)               0.353   0 (0 -- 0)               0 (0 -- 0)               0.630
  Total SVD burden, median (IQR)                1 (0 -- 1)                1 (0 -- 2)               0.000   1 (0 -- 1)               1 (0 -- 2)               0.003

*mRS, modified Ranking scale; IQR, interquartile range; BMI, body mass index; NIHSS, National Institute of Health Stroke Scale; SVD, small vessel disease; WMH, white matter hyperintensities; EPVS, enlarged perivascular spaces*.

Logistic regression was used to analyze the associations of individual SVD feature and total burden of SVD with functional outcomes at 90 days; results are presented in [Figure 2](#F2){ref-type="fig"}. In regard to individual SVD feature, lacunes (OR: 0.48, 95% CI: 0.32--0.71; OR: 0.49, 95% CI: 0.31--0.77) and WMH (OR: 0.53, 95% CI: 0.34--0.82; OR: 0.53, 95% CI: 0.33--0.85) were negatively associated with excellent outcome and good outcome. Further analysis of different location of WMH showed that PVWMH were associated with lower odds of excellent outcome and good outcome than DWMH ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). As to the total burden of SVD, 2 SVD features (OR: 0.45, 95% CI: 0.26--0.77; OR: 0.49, 95% CI: 0.27--0.89), 3 SVD features (OR: 0.13, 95% CI: 0.03--0.48; OR: 0.18, 95% CI: 0.06--0.54), and the score of total SVD burden (OR: 0.63, 95% CI: 0.50--0.80; OR: 0.65, 95% CI: 0.50--0.84) were negatively associated with excellent outcome and good outcome. Among which, three SVD features had strongest negative associations with functional outcomes.

![Associations of individual feature and total burden of small vessel disease with functional outcomes at 90 days. Binary logistic regression was used to analyze the associations between SVD and excellent outcome **(A)** or good outcome **(B)**. mRS, modified Ranking scale; OR, odds ratio; CI, confidence interval; WMH, white matter hyperintensities; EPVS, enlarged perivascular spaces; SVD, small vessel disease.](fneur-10-00808-g0002){#F2}

Adjusted associations between total SVD burden and functional outcomes at 90 days are presented in [Table 3](#T3){ref-type="table"}. After adjustment of age and sex, 2 SVD features (OR: 0.46, 95% CI: 0.26--0.82), 3 SVD features (OR: 0.13, 95% CI: 0.03--0.51), and the score of total SVD burden (OR: 0.63, 95% CI: 0.49--0.82) were negatively associated with excellent outcome; 3 SVD features (OR: 0.23, 95% CI: 0.07--0.73) and the score of total SVD burden (OR: 0.70, 95% CI: 0.53--0.93) were negatively associated with good outcome. After adjusting for age, sex, hypertension, diabetes mellitus, hypercholesterolemia, coronary heart disease, previous stroke, current smoking, alcohol consumption, proximal vessel occlusion, stroke subtype, baseline NIHSS, baseline mRS, and hospital stay, three SVD features (OR: 0.07, 95% CI: 0.01--0.41) and the score of total SVD burden (OR: 0.64, 95% CI: 0.44--0.93) remained negatively associated with excellent outcome.

###### 

Adjusted associations between total burden of small vessel disease and functional outcomes at 90 days.

  ------------------------------------------------------------------------------------------------------------
                     **Excellent outcome**\      **Good outcome**\                            
                     **(mRS ≤ 1) OR (95% CI)**   **(mRS ≤ 2) OR (95% CI)**                    
  ------------------ --------------------------- --------------------------- ---------------- ----------------
  0                  1                           1                           1                1

  1                  0.76\                       0.93\                       0.89\            1.02\
                     (0.47 -- 1.23)              (0.47 -- 1.85)              (0.51 -- 1.57)   (0.46 -- 2.29)

  2                  0.46\                       0.57\                       0.58\            0.87\
                     (0.26 -- 0.82)              (0.25 -- 1.32)              (0.31 -- 1.09)   (0.34 -- 2.24)

  3                  0.13\                       0.07\                       0.23\            0.25\
                     (0.03 -- 0.51)              (0.01 -- 0.41)              (0.07 -- 0.73)   (0.05 -- 1.20)

  Total SVD burden   0.63\                       0.64\                       0.70\            0.79\
                     (0.49 -- 0.82)              (0.44 -- 0.93)              (0.53 -- 0.93)   (0.53 -- 1.19)
  ------------------------------------------------------------------------------------------------------------

*Model 1: Bivariate logistic regression analyses with adjustment for age and sex*.

*Model 2: Bivariate logistic regression analyses with adjustment for age, sex, hypertension, diabetes mellitus, hypercholesterolemia, coronary heart disease, previous stroke, current smoking, alcohol consumption, proximal vessel occlusion, stroke subtype, baseline NIHSS, baseline mRS, and hospital stay*.

*mRS, modified Ranking scale; OR, odds ratio; CI, confidence interval; SVD, small vessel disease*.

Discussion {#s4}
==========

In the present study, we found that total SVD burden (including lacunes, WMH, and EPVS) negatively affects functional outcome in patients with acute ischemic stroke and is superior to individual SVD feature in prediction of functional outcome. A high SVD burden was associated with a higher mRS score and substantially reduced the chances to have excellent outcome rather than good outcome at 90 days, indicating that a high SVD burden might predict poorer functional outcome.

In our study, lacunes and WMH were related to 90-day functional outcome, which is in accordance with previous results that lacunes and WMH negatively affect clinical outcome in patients with acute ischemic stroke. Lacunes have been reported associated with recurrent stroke and neurological impairment over time ([@B25]). Furthermore, two large-scale studies have suggested a role for WMH in predicting early neurological deterioration and disability at 3 months after stroke ([@B6], [@B26]). However, few studies had separately evaluated the impact of PVWMH and DWMH on functional outcome after stroke. We found that PVWMH had stronger association with functional outcome than DWMH, suggesting that PVWMH are more sensitive than DWMH in predicting poor functional outcome after stroke. Previous studies have indicated that PVWMH rather than DWMH were preferentially associated with decline in total cerebral blood flow ([@B27]), and thus may be more vulnerable to hemodynamic disturbance and more prone to ischemia owing to the unstable blood supply of the periventricular watershed area ([@B28]). It is speculated that this might be one of the reasons why PVWMH have higher efficacy than DWMH in predicting functional outcome after stroke.

We also analyzed the association between EPVS and functional outcome after stroke. EPVS, the most prevalent feature of SVD in patients with stroke ([@B11]), have been reported in relation to increased risk of recurrent ischemic stroke ([@B9], [@B29]). However, no independent association between EPVS and functional outcome was found in our study. Future larger multicenter studies are needed to investigate whether EPVS have a predictive effect on functional outcome in patients with acute ischemic stroke.

SVD features frequently occur together; thus, it is necessary to quantify the total burden of SVD in order to assess the cumulative effect of small vessel injury on the whole brain. We found that the total SVD burden was superior to individual SVD feature in prediction of functional outcome, with three SVD features having the strongest negative association with functional outcome. A high SVD burden (three features) was associated with higher mRS score and substantially reduced the chances to have excellent outcome rather than good outcome at 90 days. Since not all SVD features were combined in our study, the impact of total SVD burden on functional outcome might be underestimated.

The pathogenesis linking total SVD burden and functional outcome after acute ischemic stroke is not entirely clear; various mechanisms might be involved. As total SVD burden indicates the chronic accumulation of small vessel injury, which leads to the decrease of neurological reserve capacity in brain, pre-existing SVD might be a marker of increased susceptibility of brain tissue to ischemia and other injury ([@B1], [@B10]). Besides, a higher burden of SVD and the comorbid brain disease could destroy white matter tissue microstructure and disrupt the network architecture of the brain, thus impairing the plasticity and compensatory mechanisms and slow down the brain\'s recovery from stroke ([@B30]--[@B32]). What\'s more, SVD could affect functional outcome by disrupting motor/cognitive networks that are important for learning and neurorehabilitation ([@B33]). Evidence is accumulating that total SVD burden independently contributes to progressive cognitive impairment, dementia, and gait/balance disturbances ([@B34]--[@B36]). SVD-related cognitive/executive dysfunction may impair not only motor learning but also active participation in rehabilitation and adherence to treatment guidelines, thus leading to poor functional recovery.

Our study has several limitations. First, since the evaluation of CMB is limited as SWI and GRE sequence were not routine sequences of MRI for patients with acute ischemic stroke in most hospitals of China, we only chose SVD features that were available with routine sequence of MRI to ensure feasibility of use and transferability of results on clinical practice. As not all features of SVD were combined in our study, the impact of total SVD burden on functional outcome might be underestimated. Besides, we acknowledge that our estimation of the total SVD burden still needs further validation in larger, more varied cohorts. Second, severely affected patients who were unable to tolerate MRI and patients who underwent mechanical thrombectomy and evaluated by emergency CT examination usually lack cerebral MRI data or have incomplete MRI data, so they were excluded from the study. This selection bias would probably lead to an underestimation of the association between total SVD burden and function outcome, and might limit the generalizability of the results to all stroke patients. Third, we used qualitative (Fazekas scale) assessment for evaluation of WMH, which is considered not as precise as quantitative (volumetric) assessment. However, as qualitative and quantitative WMH burden assessments have been demonstrated to be highly correlated and comparable in stroke patients ([@B6]), quick visual rating is sufficient in WMH evaluation. Despite these limitations, the strengths of our study include relatively large sample size and apprehensive evaluation of three features of SVD with unified rating systems. More importantly, our results are easily transferrable into clinical routine.

In conclusion, our study demonstrated that total SVD burden negatively associated with functional outcome at 3 months in patients with acute ischemic stroke and is superior to individual SVD feature in prediction of functional outcome. MRI-based assessment of total SVD burden might help to identify patients with poor functional outcome. We suggest that caregivers use the knowledge of total SVD burden to provide better and more personalized care, by identifying those patients at higher risk for unfavorable functional outcome and by more clearly assessing the potential of functional recovery.
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